Dasatinib inhibits PD-L1 expression via a proteasomal pathway in pancreatic ductal adenocarcinoma cells
Ching‐Chung Ko, Huiying Li, Pei‐Ming Yang · Journal of Cancer · 2025
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2025
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a 5-year survival rate of below 8%. Standard chemotherapy regimens, including gemcitabine and FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin), offer limited clinical benefits. Although immune checkpoint inhibitors (ICIs) have revolutionized cancer immunotherapy, PDAC remains largely unresponsive to ICI monotherapy. In this study, we demonstrate that dasatinib, a multi-targeted tyrosine kinase inhibitor, reduces programmed death ligand 1 (PD-L1) expression in PDAC cells via a proteasome-dependent degradation pathway.
Moreover, PD-L1 levels were correlated with dasatinib sensitivity, suggesting its utility as a predictive biomarker. These findings not only elucidate a novel mechanism of dasatinib's action but also provide a strong rationale for combining dasatinib with ICIs to overcome immune resistance and enhance therapeutic efficacy against PDAC.
Open the resolved locator · 10.7150/jca.124262
Metadata licence: OpenAlex metadata (CC0)